STOCK TITAN

Utah Medical Products (UTMD) Stock News

UTMD NASDAQ

Utah Medical Products Inc. develops, manufactures and markets disposable and reusable specialty medical devices, with a stated focus on health care for women and babies. Its products are used in areas such as blood pressure monitoring, blood collection, electrosurgery, gynecology, neonatal critical care, perinatology and urology, serving hospitals, outpatient clinics and physicians' offices.

Company updates commonly cover quarterly and annual financial performance, domestic and outside-U.S. sales trends, foreign-currency effects, product-category demand, OEM and distributor relationships, and profit margins. Recurring corporate actions include quarterly cash dividends, open-market share repurchases when disclosed, board appointments and other governance updates for the Nasdaq-listed common stock.

Rhea-AI Summary

Utah Medical Products (Nasdaq: UTMD) approved a quarterly cash dividend of $0.315 per common share, payable on January 5, 2027. The dividend represents a 1.6% increase over the prior regular quarterly cash dividend. Stockholders of record at the close of business on December 17, 2026 will receive the payment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
dividends
-
Rhea-AI Summary

Utah Medical Products (Nasdaq:UTMD) purchased 327,740 common shares in its tender offer, which expired October 27, 2026. The purchase totaled $24,580,500 at $75.00 per share, versus an offer for up to 650,000 shares. Remaining shares outstanding were 2,849,041, including 1,775 employee option shares exercised in October. The effective tender cost was $75.35 per share; a further 1% excise tax will apply to share repurchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
Rhea-AI Summary

Utah Medical Products (UTMD) purchased 322,215 common shares through its tender offer, which expired on October 27, 2026.

The company offered to buy up to 650,000 shares at $75.00 per share and purchased shares for $24,166,125. Shares outstanding stood at 2,854,566 on October 29, including 1,775 employee option exercises in October.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
Rhea-AI Summary

Utah Medical Products (UTMD) reported third-quarter revenue of $8.621 million, with earnings rising despite lower sales than a year earlier. Revenue fell 12.1%, while net income increased 6% and earnings per share rose 7%. Operating margin improved to 32.4% from 26.6%, helped by lower combined litigation and intangible-asset amortization expenses.

Nine-month revenue was $25.873 million, down 12%, while net income fell 7% and earnings per share declined 5%. Lost customers and lower Filshie device sales weighed on revenue. Femcare acquired Orion Medical Supplies at the end of August for $5.0 million including fees and duties; Orion added $619,000 in quarterly sales. Cash and investments stood at $85.2 million on September 30, with no debt. The company projects a full-year sales decline close to 7%, with continued uncertainty.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Summary

Utah Medical Products (Nasdaq: UTMD) extended its tender offer expiration to October 27, 2026, giving shareholders more time to decide.

The offer remains for up to 650,000 common shares at $75.00 per share. The new deadline is 5:00 p.m. New York City time, replacing the October 7 deadline. The company said the extension also allows shareholders to consider its calendar third-quarter 2026 financial results, scheduled for October 22. All other offer conditions remain unchanged. Shareholders participating in the offer must deliver the Letter of Transmittal, share certificates and any other required documents to Computershare Trust Company, the depositary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

Utah Medical Products (UTMD) corrected the weekday for its tender offer’s scheduled October 7 expiration from Tuesday to Wednesday.

The offer is scheduled to expire at 5:00 p.m. New York City time, unless UTMD extends it. The company is offering to purchase up to 650,000 common shares at $75.00 per share. Its SEC Form TO Offer to Purchase and Letter of Transmittal contain the offer conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Rhea-AI Summary

Utah Medical Products (UTMD) launched a tender offer on September 24, 2026, to buy up to 650,000 common shares.

The $75.00 per-share price is 17% above the stock's average daily closing price over the last twelve months and 21% above its average over the last twenty-four months. The offer is scheduled to expire at 5:00 p.m. New York City time on October 7, unless extended. The board approved the offer, but neither it nor the company recommends whether shareholders should tender.

First-half 2026 sales were 12% lower and net profits were 13% lower than in the same period of 2025. EBITDA for the last half of 2025 and first half of 2026 was $15,703,744.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary

Utah Medical Products (UTMD) plans a cash tender offer to repurchase up to 650,000 shares, about 20% of its outstanding stock, at $75.00 per share.

The price is 17% above the average daily closing price over the last twelve months and 21% above the two-year average, and is just below the two-year intraday high of $75.75. The offer is expected to commence on September 22, 2026, or as soon as possible thereafter, and will expire fifteen business days later unless extended. If oversubscribed, UTMD will first buy all shares tendered by holders of fewer than 100 shares, then purchase remaining tendered shares on a pro rata basis. The company may purchase more than 650,000 shares, and the offer is not conditioned on any minimum tender.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.60%
Tags
none
-
Rhea-AI Summary

Utah Medical Products (Nasdaq: UTMD), through its wholly owned UK subsidiary Femcare, has acquired the entire ordinary share capital of Orion Medical Supplies, a UK-based niche assembler and distributor of Harm Reduction medical device kits serving the UK and European markets. Orion’s products, which aim to reduce blood-borne infections, drug-related injuries and negative social impacts, are well accepted by the UK NHS and other European organizations where Femcare and UTMD already distribute proprietary devices.

According to Utah Medical Products, the acquisition is expected to be accretive, adding about $6 million to current consolidated annual sales and benefiting from leverage of Femcare’s existing infrastructure, substantially diluting overhead as a percentage of UK sales. The purchase price was £3.6 million, funded from cash reserves, and Orion’s operations will be transitioned into Femcare’s Romsey facilities after a transition period. Additional acquisition-related risk factors will be detailed in UTMD’s Q3 2026 Form 10-Q, expected by October 15.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
Rhea-AI Summary

Utah Medical Products (Nasdaq: UTMD) announced that its Board of Directors approved a quarterly cash dividend of $0.31 per share of common stock. The dividend is payable on October 5, 2026 to shareholders of record as of September 17, 2026, representing a 1.6% increase over the dividend declared in the same quarter of the prior year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
dividends

FAQ

What is the current stock price of Utah Medical Products (UTMD)?

Utah Medical Products (UTMD) last closed at $69.49.

What is the market cap of Utah Medical Products (UTMD)?

The market cap of Utah Medical Products (UTMD) is approximately $198.0M.